Business
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program MELBOURNE, Australia and NEW YORK, March 18, 2026
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program\nMELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors. At current trading levels, Incannex’s market capitalization is approximately $46 million — representing a significant disconnect to the Company’s $75 million cash position and resulting in a negative enterprise value. Management believes this disconnect does not reflect the Company’s financial strength or, the continued advancement of its clinical pipeline, or the external validation demonstrated by the participation of healthcare-focused institutional investors in the recently completed financing. The participation of healthcare-focused institutional investors in this financing reflects meaningful external validation of both the Company’s clinical program and the long-term value potential of IHL-42X. Incannex now holds approximately $75 million in cash with no debt, positioning the Company with a strong balance sheet as it advances IHL-42X for obstructive sleep apnea (OSA) and PSX-001 for the treatment of generalized anxiety disorder (GAD). Capital Position Supports Near- and Long-Term Development Proceeds from the recently completed financing are expected to fund the Company’s DReAMzz Phase 2 crossover dose-optimization study for IHL-42X. The study is designed to further optimize the ratio of the two active pharmaceutical ingredients within the drug candidate, with the goal of maximizing efficacy across both objective physiological endpoints and patient-reported outcomes. Funding DReAMzz with proceeds from the recent financing allows the Company to preserve the majority of its existing capital for the next stage of development, including an optimized Phase 3 program. The Company’s board-approved share buyback program remains available and carries remaining capacity, providing management with an additional tool to deliver shareholder value when market conditions warrant. Continued Progress Advancing IHL-42X Over ...